Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing

HALIFAX, Nova Scotia, April 17, 2018 (GLOBE NEWSWIRE) — Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have recommended that shareholders vote FOR all items submitted for approbation by the shareholders, including the share consolidation for a potential Nasdaq listing and the Corporation’s name change, at the annual and special meeting of shareholders to be held on May 1, 2018.